Elon Musk’s Neuralink: Bold step towards first human clinical trial

by

In a groundbreaking move, Neuralink Corp., led by tech visionary Elon Musk, has initiated a much-anticipated clinical trial, bringing their futuristic brain implant technology closer to reality. With a focus on patients with quadriplegia and ALS, the trial aims to assess the safety and functionality of mind-controlled external devices. While sparking a surge of interest in the field, the company’s primary objective remains mitigating brain injuries. Despite this remarkable stride, experts caution that widespread implementation may still be years away.

Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.

Elon Musk’s Brain Startup Neuralink Is Recruiting for Its First Human Clinical Trial

By Sarah McBride

Neuralink Corp., the brain implant startup led by billionaire Elon Musk, is recruiting patients for a clinical trial, a long-awaited step that brings the science fiction-esque technology closer to human reality. 

In a blog post, the company said it was recruiting patients with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS) for the trial. Neuralink plans to evaluate the safety and functionality of its tool allowing people to manipulate external devices with their minds.

The initial goal “is to grant people the ability to control a computer cursor or keyboard using their thoughts alone,” the company said in the post. 

The announcement marks a highly anticipated moment for the startup, which has created a wave of interest in the field of brain implants.

While Musk has discussed far-out targets for Neuralink — such as helping people learn languages or communicating thoughts mentally — he has also consistently said that its first project would be to help ameliorate brain injuries.

Several other companies working on similar technology have previously succeeded in embedding devices in brains. Synchron Inc. implanted its first device in a US patient via blood vessels rather than brain surgery. Synchron inserts its device via a surgical incision in the base of the neck and then maneuvers the implant to its destination in the brain.

Early Food and Drug Administration approval for Neuralink’s trial came in May this year with an investigational device exemption, which allows medical device makers to move ahead with human trials. The company said it had also received approval from the hospital where it will perform the first surgeries, but did not name the hospital.

The path to the next set of trials and eventual widespread deployment is a long one. In May, Victor Krauthamer, a professor at George Washington University and the former director of the division of Biomedical Physics at the FDA, noted: “It usually takes years.”

Read also:

© 2023 Bloomberg L.P.

Visited 1,297 times, 9 visit(s) today

BizNews